Efruxifermin is a Fusion Protein owned by Akero Therapeutics, and is involved in 6 clinical trials, of which 4 were completed, 1 is ongoing, and 1 is planned.

Efruxifermin (AKR-001) acts as fibroblast growth factor receptor 1, 2, 3 agonist. The drug candidate as a FGF21 analog binds to isoforms of FGF receptor in the presence of beta klotho. On binding with FGF receptor, FGF21 analogue directly regulates lipid metabolism and reduces hepatic lipid accumulation in an insulin-independent manner. The stimulation of specific FGF-R also activates TK signaling pathway with activation of an extracellular response kinase 1/2 (ERK1/2) which in turn stimulates insulin gene transcription. The drug candidate by agonizing the FGF receptors counteracts obesity, hepatic disorders and insulin resistance.

The revenue for Efruxifermin is expected to reach a total of $2.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Efruxifermin NPV Report.

Efruxifermin was originated by Amgen and is currently owned by Akero Therapeutics.

Efruxifermin Overview

Efruxifermin (AKR-001) is under development for the treatment of non-alcoholic steatohepatitis (NASH), type 2 diabetes and cirrhosis due to NASH. The drug candidate is a long-acting fibroblast growth factor 21 (FGF21) analog. It is a fusion protein obtained by the fusion of Fc domain of human IgG1 to the N-terminus of human mature FGF21 via a linker peptide. The drug candidate acts by targeting fibroblast growth factor receptors 1, 2, 3. It is administered through subcutaneous route. It was also under development for obesity.

Akero Therapeutics Overview

Akero Therapeutics is a clinical-stage cardio-metabolic company. The company develops transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero’s lead product candidate, efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, is currently being evaluated in a Phase 2b clinical trial as a potential treatment for NASH. It also develop medicines for the treatment of metabolic diseases. The company is funded by Atlas Venture, ATP, venBio Partners and Versant Ventures. The company has offices in Massachusetts and California. Akero Therapeutics is headquartered in California, US.

The operating loss of the company was US$100.9 million in FY2021, compared to an operating loss of US$80.2 million in FY2020. The net loss of the company was US$100.8 million in FY2021, compared to a net loss of US$79.2 million in FY2020.

Quick View – Efruxifermin

Report Segments
  • Innovator
Drug Name
  • Efruxifermin
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Gastrointestinal
  • Metabolic Disorders
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.